Poly Medicure Limited has informed the Exchange regarding Board meeting held on August 08, 2025.
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Poly Medicure's board met on August 8, 2025 and approved unaudited Q1 FY26 results. Standalone revenue from operations rose modestly to Rs 384.05 crore (~4.5% YoY) while total income (including other income) grew ~10.6% to Rs 425.14 crore. Standalone profit after tax grew ~21.6% to Rs 87.93 crore, and consolidated PAT grew ~25.7% YoY to Rs 93.08 crore, lifting standalone EPS to Rs 8.68 from Rs 7.53. The statutory auditor (Doogar & Associates) issued an unmodified review report on both standalone and consolidated results. The board also re-appointed two independent directors for five-year terms, elevated long-time operations head Mr. Pankaj Kumar Gupta as Executive Director, granted 3,400 stock options under ESOP 2020 at Rs 100 per share, and re-appointed M/s Jai Prakash & Company as cost auditors for FY 2025-26.
Strong consolidated profit growth of over 25% and improving margins signal healthy operating momentum and may support the stock sentiment. The leadership reshuffle brings an experienced insider into the executive director role, while modest ESOP grants and clean audit report suggest stability rather than disruption for shareholders.